A novel cancer-associated membrane signature predicts prognosis and therapeutic response for lung adenocarcinoma.

ABSTRACT: Lung adenocarcinoma (LUAD) is a leading cause of cancer-related death, and reliable biomarkers for prognosis and treatment guidance remain limited. Membrane proteins play key roles in tumor progression and therapeutic response, yet their clinical utility in LUAD remains underexplored. We integrated scRNA-seq, spatial transcriptomics, and bulk RNA-seq datasets from multiple LUAD cohorts to identify cancer-specific membrane proteins derived from epithelial subpopulations. Based on these results, we constructed a prognostic signature, LCaMPS, and evaluated its predictive performance using multiple datasets. The expression of model genes was confirmed at both the bulk RNA and protein levels. Associations with the tumor microenvironment (TME) and drug sensitivity were further analyzed. A distin

SUBMITTER: Tu B 

PROVIDER: S-EPMC12263979 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature